Brensocatib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Brensocatib. Educational only — not medical advice.
Labeled uses
BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.
Source: FDA labeling via NIH DailyMed (set b56986ae…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.